Helen Gall

1.5k total citations
16 papers, 1.2k citations indexed

About

Helen Gall is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, Helen Gall has authored 16 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 5 papers in Molecular Biology and 3 papers in Hematology. Recurrent topics in Helen Gall's work include Cancer therapeutics and mechanisms (4 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Cancer Treatment and Pharmacology (4 papers). Helen Gall is often cited by papers focused on Cancer therapeutics and mechanisms (4 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Cancer Treatment and Pharmacology (4 papers). Helen Gall collaborates with scholars based in Netherlands, United States and Belgium. Helen Gall's co-authors include Herbert M. Pinedo, Rik J. Scheper, Jan B. Vermorken, Elisabeth Bloemena, Chris J.L.M. Meijer, Janet H. Ransom, A.M.E. Claessen, Sybren L. Meijer, Harm van Tinteren and Michael G. Hanna and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and The Lancet Oncology.

In The Last Decade

Helen Gall

16 papers receiving 1.2k citations

Peers

Countries citing papers authored by Helen Gall

Since Specialization

Citations

This map shows the geographic impact of Helen Gall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Helen Gall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Helen Gall more than expected).

Fields of papers citing papers by Helen Gall

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Helen Gall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Helen Gall. The network helps show where Helen Gall may publish in the future.

Co-authorship network of co-authors of Helen Gall

This figure shows the co-authorship network connecting the top 25 collaborators of Helen Gall. A scholar is included among the top collaborators of Helen Gall based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Helen Gall. Helen Gall is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab 2014 ·Journal for ImmunoTherapy of Cancer ·Saskia J. Santegoets, Anita G.M. Stam, Sinéad M. Lougheed, Helen Gall, Karin Jooss, Natalie Sacks, Kristen Hege, Israel Lowy, Rik J. Scheper, Winald R. Gerritsen, Alfons JM van den Eertwegh, Tanja D. de Gruijl	91
2	Translation and linguistic validation of the FACT-EGFRI-18 quality of life instrument from English into Dutch 2013 ·European Journal of Oncology Nursing ·Christine B. Boers‐Doets, Hans Gelderblom, Mario E. Lacouture, Jason Bredle, Joel B. Epstein, (unknown), Helen Gall, Jan Ouwerkerk, (unknown), J.W.R. Nortier, Ad A. Kaptein	5
3	Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial 2012 ·The Lancet Oncology ·Alfons JM van den Eertwegh, Jurjen Versluis, H. Pieter van den Berg, Saskia J. Santegoets, R. Jeroen A. van Moorselaar, Tim M. van der Sluis, Helen Gall, Thomas C. Harding, Karin Jooss, Israel Lowy, Herbert M. Pinedo, Rik J. Scheper, Anita G.M. Stam, B. Mary E. von Blomberg, Tanja D. de Gruijl, Kristen Hege, Natalie Sacks, Winald R. Gerritsen	290
4	T cell profiling reveals high CD4+CTLA-4+ T cell frequency as dominant predictor for survival after Prostate GVAX/ipilimumab treatment 2012 ·Cancer Immunology Immunotherapy ·Saskia J. Santegoets, Anita G.M. Stam, Sinéad M. Lougheed, Helen Gall, Petra E.T. Scholten, Martine Reijm, Karin Jooss, Natalie Sacks, Kristen Hege, Israel Lowy, Jean-Marie Cuillerot, B. Mary E. von Blomberg, Rik J. Scheper, Alfons J.M. van den Eertwegh, Winald R. Gerritsen, Tanja D. de Gruijl	78
5	A Phase I Safety and Pharmacologic Study of a Twice Weekly Dosing Regimen of the Oral Taxane BMS-275183 2007 ·Clinical Cancer Research ·Linda E. Bröker, Stephan A. Veltkamp, Elisabeth I. Heath, Bart C. Kuenen, Helen Gall, (unknown), Susan Parker, L. Kayitalire, Patricia LoRusso, Jan H.M. Schellens, Giuseppe Giaccone	21
6	A phase I and pharmacokinetic study of LAF389 administered to patients with advanced cancer 2006 ·Anti-Cancer Drugs ·Herlinde Dumez, Helen Gall, Renaud Capdeville, Catherine Dutreix, Allan T. van Oosterom, Giuseppe Giaccone	45
7	Phase I Trial with BMS-275183, a Novel Oral Taxane with Promising Antitumor Activity 2006 ·Clinical Cancer Research ·Linda E. Bröker, Filip De Vos, Cees J. van Groeningen, Bart C. Kuenen, Helen Gall, Michael H. Woo, Maurizio Voi, Jourik A. Gietema, Elisabeth G.E. de Vries, Giuseppe Giaccone	19
8	Continuous administration of irinotecan by hepatic arterial infusion: a phase I and pharmacokinetic study. 2002 ·PubMed ·J.M.G.H. van Riel, Cees J. van Groeningen, (unknown), Helen Gall, (unknown), G. Gruia, Herbert M. Pinedo, W. J. F. van der Vijgh, Giuseppe Giaccone	52
9	Phase I Clinical and Pharmacokinetic Study of Oral S-1 in Patients With Advanced Solid Tumors 2000 ·Journal of Clinical Oncology ·Cees J. van Groeningen, Godefridus J. Peters, Jan H. Schornagel, Helen Gall, Paul Noordhuis, (unknown), (unknown), (unknown), Herbert M. Pinedo, Axel R. Hanauske, Giuseppe Giaccone	132
10	Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial 1999 ·The Lancet ·Jan B. Vermorken, A.M.E. Claessen, Harm van Tinteren, Helen Gall, (unknown), Sybren L. Meijer, Rik J. Scheper, Chris J.L.M. Meijer, Elisabeth Bloemena, Janet H. Ransom, Michael G. Hanna, Herbert M. Pinedo	379
11	Pharmacokinetics of amifostine and its metabolites in the plasma and ascites of a cancer patient 1996 ·Cancer Chemotherapy and Pharmacology ·A.E.C. Korst, Helen Gall, J. B. Vermorken, W. J. F. van der Vijgh	20
12	The basis of cancer fatigue: where does it come from? 1996 ·European Journal of Cancer Care ·Helen Gall	13
13	Expanding the role of the nurse in clinical trials: the nursing summaries 1996 ·Cancer Nursing ·Paola Di Giulio, C. Arrigo, Helen Gall, (unknown), (unknown), (unknown)	25
14	Safe handling of antineoplastic drugs 1994 ·Cancer Nursing ·(unknown), (unknown), (unknown), Helen Gall, (unknown), (unknown), (unknown), (unknown), Jan Ouwerkerk, (unknown)	30
15	Phase I study of spiroplatin 1991 ·European Journal of Cancer and Clinical Oncology ·Bea C. Tanis, Jan B. Vermorken, W.W. ten Bokkel Huinink, (unknown), Helen Gall, Allan T. van Oosterom, (unknown), J. G. McVie, W. J. F. van der Vijgh, Herbert M. Pinedo	5
16	Phase I study of Brequinar sodium (NSC 368390) in patients with solid malignancies 1990 ·Cancer Chemotherapy and Pharmacology ·Gilberto Schwartsmann, P. Dodion, Jan B. Vermorken, W.W. ten Bokkel Huinink, (unknown), Benjamin Winograd, Helen Gall, (unknown), W. J. F. van der Vijgh, (unknown), (unknown), Herbert M. Pinedo	36

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact